Description[edit]

Overview

Advaxis, Inc. is the live Listeria monocytogenes vaccine company. We bioengineer live attenuated Listeria to secrete antigenic targets as an antigen-adjuvant fusion proteins.  Our biotechnology uses a modified infectious microorganism to activate the immune system to treat cancer, infectious disease or allergic syndromes. Based upon over a 15 years of innovative work done by Yvonne Paterson, Ph.D., Professor of Microbiology at the University of Pennsylvania, it has been found that the unique microbe Listeria monocytogenes is capable of stimulating numerous aspects of the immune system simultaneously; including innate immunity, both arms of the adaptive immune response, as well as many non-classical immune responses in an extremely effective therapeutic response to existing cancers and other diseases.

Why Advaxis is different from other immunotherapies:

* It is the only commercial bacteria vector
* It utilizes a pre-existing immune reaction that is far more comprehensive than the reactions other approaches create and directs it to the tumor
* It reduces by 80% the regulatory T cells inside tumors that hinder immune attack
* It has shown consistent elimination of 70% of pre-existing tumors in preclinical testing among normal animals
* Once tumors have been cleared in these animals, they cannot be reintroduced.
* Initial human results demonstrate safe administration and encouraging early signs of efficacy

Innovation[edit]

Activities[edit]

Financial Profiles[edit]

Stock Symbol[edit]

No jobs were found for this particular company. Please visit the job board to search for more.

Leave a Reply